144 related articles for article (PubMed ID: 28874891)
1. Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.
Gotfrit J; Vickers M; Sud S; Asmis T; Cripps C; Goel R; Hsu T; Jonker D; Goodwin R
Curr Oncol; 2017 Aug; 24(4):234-239. PubMed ID: 28874891
[TBL] [Abstract][Full Text] [Related]
2. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of raltitrexed plus S-1
Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
[TBL] [Abstract][Full Text] [Related]
4. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.
Calcagno F; Lenoble S; Lakkis Z; Nguyen T; Limat S; Borg C; Jary M; Kim S; Nerich V
Clin Med Insights Oncol; 2016; 10():59-66. PubMed ID: 27398042
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Novakova-Jiresova A; Kopeckova K; Boublikova L; Chloupkova R; Melichar B; Petruzelka L; Finek J; Fiala O; Grell P; Batko S; Linke Z; Kiss I; Prausova J; Buchler T
Cancer Manag Res; 2020; 12():5365-5372. PubMed ID: 32753954
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
9. Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study.
Wang RT; Zhao Y; Wang AL; Wang YT; Yin ZP; Chen K
Int J Gen Med; 2021; 14():5363-5373. PubMed ID: 34522132
[TBL] [Abstract][Full Text] [Related]
10. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
12. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
[TBL] [Abstract][Full Text] [Related]
15. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
19. Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting.
Hatori M; Kawakami K; Wakatsuki T; Shinozaki E; Kobayashi K; Aoyama T; Nakano Y; Suzuki K; Yamaguchi K; Hama T
Dose Response; 2021; 19(4):15593258211047658. PubMed ID: 34675759
[TBL] [Abstract][Full Text] [Related]
20. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre.
Chamberlain F; Farag S; Williams-Sharkey C; Collingwood C; Chen L; Mansukhani S; Engelmann B; Al-Muderis O; Chauhan D; Thway K; Fisher C; Jones RL; Gennatas S; Benson C
Clin Sarcoma Res; 2020; 10():1. PubMed ID: 31911828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
